PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth of post-market surveillance system also may require more resources.
You may also be interested in...
FDA Aims To Tap Sentinel Data Network For Drug Effectiveness Studies
New ‘Guardian’ program to monitor post-market effectiveness through the Sentinel electronic data network will take five years to build, FDA’s Woodcock says.
Califf Continues Clinical Trial Reform Crusade With Confirmation Vote Pending
FDA Commissioner nominee outlines ideas for improving clinical trials in written responses to senators' questions; HELP Committee to vote Jan. 12.
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.